The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Amgen Reports Positive Phase 3 Results for Subcutaneous Tepezza Delivery

Key Facts

1The Phase 3 trial for subcutaneous Tepezza met its primary and key secondary endpoints for treating Thyroid Eye Disease (TED).

2The study showed that 77% of patients achieved a significant proptosis response, with a reduction of greater than 3 mm.

3The new formulation is administered via an on-body injector (OBI), providing an alternative to the standard intravenous infusion.

Create Free Account

Version History

1 additional source confirmed this story

Amgen (AMGN) has announced successful topline results from its Phase 3 clinical trial evaluating a subcutaneous delivery method for Tepezza. The study, which focused on treating Thyroid Eye Disease (TED), met both its primary and key secondary endpoints. Data revealed that 77% of patients achieved a significant proptosis response, showing a reduction of more than 3 mm in eye protrusion. This new formulation is administered through an on-body injector (OBI), offering a more convenient alternative to traditional intravenous infusions. The successful trial marks a significant milestone for Amgen as it seeks to expand delivery options and improve patient adherence. While the news is positive for the company's biotech portfolio, Amgen continues to manage broader financial factors such as its debt levels.